MedTrace Logo

Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis

NCT00195819 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2011-06-28

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the safety and clinical efficacy of adalimumab in subjects with active ankylosing spondylitis

Conditions

Interventions

BIOLOGICAL

adalimumab (D2E7)

Adalimumab 40 mg every other week (eow)

BIOLOGICAL

placebo

Placebo every other week (eow)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2004-10-31
Completion
2009-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00195819 on ClinicalTrials.gov